9
项与 Autologous Adipose tissue derived Mesenchymal Stem Cells(R Bio) 相关的临床试验A 48-Weeks, Phase 2b/3a, Double-Blind, Randomized, Placebo Controlled, Multi-center, Superiority Study to Evaluate the Efficacy and Safety of JointStem, Autologous Adipose Tissue Derived Mesenchymal Stem Cells in Patients Diagnosed as Knee Osteoarthritis
This study is a double-blind, randomized, placebo controlled, multi-center, superiority study to evaluate the efficacy and safety of JointStem, autologous adipose tissue derived mesenchymal stem cells (AdMSC), in patients diagnosed as knee osteoarthritis. Following a 2-week screening period, approximately 140 subjects will be randomly assigned into one of the following two arms in a 1:1 ratio (1 JointStem : 1 Placebo). After each subject completes 48-Weeks visit (Visit 8) and the data management team confirms all individual data have no issue, the individual database will be locked and the blinding will be open for the statistical analysis.
Evaluation of the safety and feasibility of intra-arterial injection of autologous stem cells derived from adipose tissue in stroke patients.
Single-center, Randomized, Open Label, Negative-controlled Investigator Initiated Trial to Evaluate the Efficacy and Safety of Intra-articular Injection of ADMSC(Autologous Adipose Tissue Derived Mesenchymal Stem Cells) After High Tibial Osteotomy Compared to Negative Control in the Osteoarthritis Patients.
The purpose of this study is to evaluate the efficacy and safety of intra-articular injection of autologous adipose tissue derived mesenchymal stem cells compared after high tibial osteotomy to negative control in the osteoarthritis patients
100 项与 Autologous Adipose tissue derived Mesenchymal Stem Cells(R Bio) 相关的临床结果
100 项与 Autologous Adipose tissue derived Mesenchymal Stem Cells(R Bio) 相关的转化医学
100 项与 Autologous Adipose tissue derived Mesenchymal Stem Cells(R Bio) 相关的专利(医药)
100 项与 Autologous Adipose tissue derived Mesenchymal Stem Cells(R Bio) 相关的药物交易